Bristol Myers Squibb's Mavacamten Aces Late-Stage Trial In Cardiomyopathy


Bristol Myers Squibb Co's BMY VALOR-HCM Phase 3 study evaluating mavacamten in adults with obstructive hypertrophic cardiomyopathy (obstructive HCM) met its primary endpoint at Week 16.

  • The trial included symptomatic obstructive HCM patients who are eligible for septal reduction therapy (SRT). 
  • The safety of mavacamten was consistent with previous studies.
  • "We look forward to sharing the results from VALOR-HCM at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in April," said Roland Chen, M.D., Senior Vice President, Cardiovascular Development at Bristol Myers Squibb. 
  • Related: Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay.
  • The 100-subject trial includes three treatment periods: a 16-week placebo-controlled period, a 16-week active treatment period where all patients will receive mavacamten, and a 96-week long-term extension period where all patients will continue to receive mavacamten.
  • Obstructive HCM is a chronic, progressive disease in which excessive heart muscle contraction and reduced ability of the left ventricle to fill can make it difficult for blood to circulate.
  • Price Action: BMY shares are up 0.26% at $67.95 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!